Skip to content
10-Q

Quarterly Report

Compass Therapeutics, Inc. CMPX

0001171843-26-003006

← back to feed
Filed
May 5, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 30, 2026 180.09M sh
Capex Q1 2026 · Mar 31, 2026 $82K
Capex Q1 2026 · Mar 31, 2025 $18K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$17.27M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$13.21M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $55.17M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $30.64M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $41.05M
Stockholders Equity Q1 2026 · Mar 31, 2026 $186.47M
Stockholders Equity Q1 2026 · Dec 31, 2025 $196.79M
Stockholders Equity Q1 2026 · Mar 31, 2025 $110.28M
Stockholders Equity Q1 2026 · Dec 31, 2024 $125.23M
Current Liabilities Q1 2026 · Mar 31, 2026 $10.28M
Current Liabilities Q1 2026 · Dec 31, 2025 $13.97M
Total Liabilities Q1 2026 · Mar 31, 2026 $18.7M
Total Liabilities Q1 2026 · Dec 31, 2025 $22.8M
Current Assets Q1 2026 · Mar 31, 2026 $195.69M
Current Assets Q1 2026 · Dec 31, 2025 $209.82M
Total Assets Q1 2026 · Mar 31, 2026 $205.17M
Total Assets Q1 2026 · Dec 31, 2025 $219.59M
Eps Basic Q1 2026 · Mar 31, 2026 −$0.10
Eps Basic Q1 2026 · Mar 31, 2025 −$0.12
Sga Expense Q1 2026 · Mar 31, 2026 $6.91M
Sga Expense Q1 2026 · Mar 31, 2025 $4.91M
Rd Expense Q1 2026 · Mar 31, 2026 $13.39M
Rd Expense Q1 2026 · Mar 31, 2025 $13.05M
Net Income Q1 2026 · Mar 31, 2026 −$18.32M
Net Income Q1 2026 · Mar 31, 2025 −$16.63M
Operating Income Q1 2026 · Mar 31, 2026 −$20.3M
Operating Income Q1 2026 · Mar 31, 2025 −$17.97M
Shares Diluted Q1 2026 · Mar 31, 2025 138.2M sh